
- © Chantal Lagresle-Peyrou
- , et al.
- 2022
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
- Chantal Lagresle-Peyrou 1
- Emmanuelle Six 1
- Isabelle André-Schmutz 1
- Marina Cavazzana 1
- Salima Hacein-Bey-Abina 1
- 1 - Biotherapy Clinical Investigation Center - Groupe Hospitalier Universitaire Ouest - Assistance Publique-Hôpitaux de Paris - INSERM Paris
Jun 29, 2022
Abstract
More than 20 years ago, X-linked severe combined immunodeficiency (SCID-X1) appeared to be the best condition to test the feasibility of hematopoietic stem cell gene therapy. The seminal SCID-X1 clinical studies, based on first-generation gammaretroviral vectors, demonstrated good long-term immune reconstitution in most treated patients despite the occurrence of vector-related leukemia in a few of them. This gene therapy has successfully enabled correction of the T cell defect. Natural killer and B cell defects were only partially restored, most likely due to the absence of a conditioning regimen. The success of these pioneering trials paved the way for the extension of gene-based treatment to many other diseases of the hematopoietic system, but the unfortunate serious adverse events led to extensive investigations to define the retrovirus integration profiles. This review puts into perspective the clinical experience of gene therapy for SCID-X1, with the development and implementation of new generations of safer vectors such as self-inactivating gammaretroviral or lentiviral vectors as well as major advances in integrome knowledge.
Related Content
-
Primer
Orthogonal Validation in Genome Editing Discovery Work -
Primer
Solvent Precipitation Method Increases Protein Recovery for Proteomics -
Protocol
Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47phox-Deficient Chronic Granulomatous Disease -
Protocol
High-Throughput In Vitro, Ex Vivo, and In Vivo Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction -
Protocol
Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells - More
Comments
Be the first to comment on this protocol.